Neonatal vaccination refers to the administration of vaccines to infants within the first month of life, aiming to provide early protection against infectious diseases. While some vaccines are given shortly after birth, others are scheduled in subsequent weeks, following a carefully designed immunization schedule. Common neonatal vaccines include those targeting hepatitis B, which is often administered shortly after birth to prevent perinatal transmission. Additionally, vaccines against tuberculosis, polio, and other diseases are typically initiated in the first few weeks of life. Neonatal vaccination is crucial as it establishes early immunity in infants who are particularly vulnerable to severe infections. It also contributes to the concept of "herd immunity," helping protect those who are unable to receive vaccinations due to medical reasons. Ensuring high vaccination coverage in neonates is a public health priority, as it prevents the spread of infectious diseases and minimizes the risk of outbreaks. Neonatal vaccination programs are continuously updated to incorporate new vaccines and enhance protection against a broader range of pathogens, contributing to improved global child health.
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Racial disparities in pediatric pneumonia in Brazil: The role of structural racism forging inequalities in acess to vaccines
Livia Daflon Silva, Federal University of State of Rio de Janeiro, Brazil
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States